Physician profile
Antonio Moran
NPI 1396735908
$24,576.92
in general payments reported to CMS, 2019-2025
84 companies · $5,788 in 2025
The $5,788 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,875 · 2020: $621 · 2021: $1,466 · 2022: $4,480 · 2023: $4,437 · 2024: $4,909 · 2025: $5,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $809 · Education: $776 · Long Term Medical Supply Or Device Loan: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,366.24 |
| Consulting Fee | $808.96 |
| Education | $776.19 |
| Long Term Medical Supply Or Device Loan | $183.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,744.55 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,424.15 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pfizer INC. | $1,302.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,240.21 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,176.54 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Daiichi Sankyo INC. | $1,040.87 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $902.24 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $869.56 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $774.97 | 2019-2024 | Kyprolis, Blincyto, Lumakras |
| Genzyme Corporation | $742.81 | 2019-2025 | |
| Incyte Corporation | $724.43 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Seagen INC. | $651.85 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $645.81 | 2019-2025 | Ninlaro, Fruzaqla |
| Astellas Pharma US INC | $544.08 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Genentech USA, INC. | $525.85 | 2019-2025 | Polivy, Phesgo, Tecentriq |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $492.68 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $471.11 | 2024-2025 | Clonoseq |
| Gilead Sciences, INC. | $453.11 | 2022-2025 | Trodelvy |
| Celgene Corporation | $432.87 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Regeneron Healthcare Solutions, INC. | $423.22 | 2019-2025 | Libtayo, Lynozyfic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.07 | 2019-2025 | Gilotrif |
| Bayer Healthcare Pharmaceuticals INC. | $382.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $372.94 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $353.33 | 2021-2025 | |
| Exelixis INC. | $349.14 | 2019-2025 | Cabometyx |
| Taiho Oncology, INC. | $331.45 | 2019-2025 | |
| Kite Pharma, INC. | $303.94 | 2021-2025 | Yescarta |
| Lilly USA, LLC | $291.49 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Octapharma USA, INC. | $281.23 | 2022-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Octagam Immune Globulin (Human), Panzyga |
| Alexion Pharmaceuticals, INC. | $275.12 | 2019-2024 | Ultomiris |
| Puma Biotechnology, INC. | $256.98 | 2019-2025 | Nerlynx |
| Sobi, INC | $249.08 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $244.58 | 2019-2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $236.10 | 2023-2025 | Monoferric, Cosela |
| Mirati Therapeutics, INC. | $195.02 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $189.17 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $180.25 | 2019-2025 | |
| Stemline Therapeutics INC. | $171.17 | 2023-2025 | Orserdu |
| G1 Therapeutics, INC. | $168.14 | 2022-2023 | Cosela |
| Array Biopharma INC | $155.01 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Medtronic, INC. | $141.86 | 2024 | Signia |
| Janssen Scientific Affairs, LLC | $136.87 | 2024 | Rybrevant |
| Kyowa Kirin, INC. | $136.01 | 2019-2025 | |
| Caris Mpi, INC. | $132.19 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $130.81 | 2022 | |
| Adma Biomanufacturing LLC | $126.18 | 2022-2025 | |
| Iovance Biotherapeutics, INC. | $119.83 | 2025 | Amtagvi |
| Beigene USA, INC. | $118.47 | 2023-2025 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $118.11 | 2022-2024 | Besremi |
| Menarini Silicon Biosystems, INC. | $110.52 | 2024-2025 | |
| Csl Behring | $98.80 | 2019-2024 | Hizentra |
| Boston Scientific Corporation | $95.19 | 2021 | |
| Tersera Therapeutics LLC | $92.41 | 2021-2025 | Zoladex, Quzyttir |
| Adc Therapeutics America, INC. | $87.89 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $64.68 | 2023-2024 | Qinlock |
| Tesaro, INC. | $64.44 | 2019 | |
| Morphosys, US INC. | $55.27 | 2022-2023 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $50.18 | 2019-2023 | Tazverik |
| Janssen Pharmaceuticals, INC | $49.12 | 2019 | |
| Novocure INC. | $44.40 | 2025 | Optune Lua (Novottf-200t) |
| Cti Biopharma Corp. | $43.08 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $42.70 | 2023-2025 | Enjaymo, Sylvant |
| Sun Pharmaceutical Industries INC. | $40.84 | 2025 | |
| Acrotech Biopharma INC. | $39.74 | 2022 | |
| Beone Medicines USA, INC. | $37.42 | 2025 | Tevimbra, Brukinsa |
| Legend Biotech USA INC. | $37.00 | 2025 | Carvykti |
| Argenx US, INC. | $35.13 | 2024 | Vyvgart Hytrulo |
| Tolmar Pharmaceuticals, INC. | $34.10 | 2022 | |
| Coherus Oncology, INC. | $32.93 | 2020-2023 | |
| Immunocore Limited | $29.02 | 2025 | Kimmtrak |
| Nuvation Bio INC. | $28.09 | 2025 | Ibtrozi |
| Sanofi-Aventis U.S. LLC | $24.93 | 2019 | |
| Agios Pharmaceuticals, INC. | $24.46 | 2025 | Pyrukynd |
| Invivyd INC | $22.02 | 2025 | Pemgarda |
| Dova Pharmaceuticals | $21.31 | 2019 | |
| Spectrum Pharmaceuticals INC. | $20.62 | 2025 | Rolvedon |
| Geron Corporation | $16.38 | 2025 | Rytelo |
| Eusa Pharma (US) LLC | $15.16 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.14 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.98 | 2020 | |
| Global Blood Therapeutics, INC. | $13.92 | 2021 | |
| Clovis Oncology, INC. | $12.72 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.31 | 2019 | |
| Secura Bio, INC. | $10.45 | 2020 |
Drugs and devices associated with these payments
Enhertu $1,131Keytruda $563Imfinzi $551Clonoseq $471Darzalex $415Rybrevant $380Tukysa $366Lenvima $343Xtandi $329Tecvayli $321Sarclisa $304Libtayo $261Padcev $258Adcetris $256Opdivo $254Inqovi $248Lonsurf $248Verzenio $247Jaypirca $247Talzenna $242Krazati $236Imbruvica $235Ibrance $234Orgovyx $233Lynparza $227Talvey $226Vonjo $222Yescarta $214Elrexfio $210Tavalisse $201Rezlidhia $201Jakafi $188Calquence $188Reblozyl $179Fabhalta $175Trodelvy $174Opdualag $174Orserdu $171Nubeqa $164Monoferric $163Stivarga $157Vitrakvi $157Kisqali $156Cabometyx $149Bosulif $146Ninlaro $145Venclexta $142Signia $142Mi Cancer Seek $132Fruzaqla $132Mektovi $131Braftovi $131Tibsovo $130Zepzelca $130Cosela $126Kyprolis $125Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) $124Brukinsa $120Amtagvi $120Oxbryta $119Tagrisso $116Besponsa $115Octagam Immune Globulin (Human) $113Pluvicto $113Cellsearch $111Retevmo $105Epkinly $102Scemblix $101Poteligeo $97.85Ojjaara $93.25Jemperli $92.34Zejula $92.34Comirnaty $92.09Polivy $91.57Besremi $82.11Nerlynx $79.24Ultomiris $79.04Welireg $73.71Gilotrif $73.65Pomalyst $71.57Piqray $71.29Inlyta $70.17Doptelet $69.99Monjuvi $66.99Hizentra $65.51Blincyto $64.88Qinlock $64.68Lumakras $64.51Vyloy $62.91Phesgo $62.65Lorbrena $61.96Promacta $61.84Alecensa $56.20Tecentriq $56.20Avastin $56.20Rozlytrek $56.20Zynlonta $54.55Zynyz $48.29Zoladex $46.93Optune Lua (Novottf-200t) $44.40
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.